VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.
Yang Li,Fan Zhang,Nobuo Nagai,Zhongshu Tang,Shuihua Zhang,Pierre Scotney,Johan Lennartsson,Chaoyong Zhu,Yi Qu,Changge Fang,Jianyuan Hua,Osamu Matsuo,Guo-Hua Fong,Hao Ding,Yihai Cao,Kevin G Becker,Andrew Nash,Carl-Henrik Heldin,Xuri Li
DOI: https://doi.org/10.1172/JCI33673
IF: 19.456
2008-01-01
Journal of Clinical Investigation
Abstract:Despite its early discovery and high sequence homology to the other VEGF family members, the biological functions of VEGF-B remain poorly understood. We revealed here a novel function for VEGF-B as a potent inhibitor of apoptosis. Using gene expression profiling of mouse primary aortic smooth muscle cells, and confirming the results by real-time PCR using mouse and rat cell fines, we showed that VEGF-B inhibited the expression of genes encoding the proapoptotic BH3-only proteins and other apoptosis- and cell death-related proteins, including p53 and members of the caspase family, via activation of VEGFR-1. Consistent with this, VEGF-B treatment rescued neurons from apoptosis in the retina and brain in mouse models of ocular neurodegenerative disorders and stroke, respectively. Interestingly, VEGF-B treatment at the dose effective for neuronal survival did not cause retinal neovascularization, suggesting that VEGF-B is the first member of the VEGF family that has a potent antiapoptotic effect while lacking a general angiogenic activity. These findings indicate that VEGF-B may potentially offer a new therapeutic option for the treatment of neurodegenerative diseases.
What problem does this paper attempt to address?